Philip S Wells

List of Publications by Year
in descending order

190 papers	24,360 citations	70961 41 h-index	7136 153 g-index
195 all docs	195 docs citations	195 times ranked	15240 citing authors

#	Article	IF	Citations
1	A cross-sectional study of the interrelationship between burnout, empathy and resilience in academic physicians. Psychology, Health and Medicine, 2022, 27, 1813-1820.	1.3	4
2	VTE Prophylaxis in Critically Ill Adults. Chest, 2022, 161, 418-428.	0.4	27
3	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, 29-35.	2.0	33
4	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2022, 19, e1003905.	3.9	19
5	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thrombosis Research, 2022, 211, 85-87.	0.8	3
6	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.4	58
7	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups. Annals of Internal Medicine, 2022, 175, 244-255.	2.0	27
8	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. Thrombosis and Haemostasis, 2022, 122, 1169-1176.	1.8	4
9	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. Thrombosis Research, 2022, 213, 57-64.	0.8	2
10	The impact of Stress Management and Resilience Training (SMART) on academic physicians during the implementation of a new Health Information System: An exploratory randomized controlled trial. PLoS ONE, 2022, 17, e0267240.	1.1	6
11	Standardization of risk prediction model reporting in cancerâ€associated thrombosis: Communication from the ISTHâSSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	1.9	3
12	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Advances, 2022, 6, 4605-4616.	2.5	7
13	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. Journal of Thrombosis and Thrombolysis, 2021, 51, 720-724.	1.0	4
14	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 197, 13-15.	0.8	8
15	Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report. Thrombosis Journal, 2021, 19, 23.	0.9	1
16	Longâ€term risk of recurrent venous thromboembolism after a first contraceptiveâ€related event: Data from REVERSE cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1526-1532.	1.9	12
17	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Thrombosis Research, 2021, 202, 151-154.	0.8	11
18	Direct oral anticoagulant use in special populations. Current Opinion in Pulmonary Medicine, 2021, 27, 311-318.	1.2	0

#	Article	IF	Citations
19	Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ, The, 2021, 373, n1205.	3.0	38
20	Longâ€term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	1.9	19
21	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.4	357
22	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	2.0	60
23	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A crossâ€sectional study using the Canadian Community Health Survey. Cancer Medicine, 2021, 10, 7601-7609.	1.3	1
24	Media portrayals of pulmonary embolism. Thrombosis Research, 2021, 206, 52-54.	0.8	0
25	Costâ€“utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. Cmaj, 2021, 193, E1551-E1560.	0.9	9
26	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. Thrombosis Research, 2021, 208, 79-82.	0.8	4
27	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 58-65.	0.8	5
28	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2139-2139.	0.6	0
29	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica, 2020, 105, 1436-1442.	1.7	19
30	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist, 2020, 25, 1075-1083.	1.9	9
31	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thrombosis Research, 2020, 196, 437-443.	0.8	0
32	Association of Splanchnic Vein Thrombosis on Survival: 15â€Year Institutional Experience With 1561 Cases. Journal of the American Heart Association, 2020, 9, e016600.	1.6	7
33	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 195-208.	0.8	7
34	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	0.8	10
35	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.4	531
36	Risk Stratification of Pulmonary Embolism. Critical Care Clinics, 2020, 36, 437-448.	1.0	3

#	Article	IF	Citations
37	Venous thromboembolism prevention in intracerebral hemorrhage: A systematic review and network meta-analysis. PLoS ONE, 2020, 15, e0234957.	1.1	8
38	Predictive analytics by deep machine learning: A call for nextâ€gen tools to improve health care. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 181-182.	1.0	4
39	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. American Journal of Kidney Diseases, 2020, 76, 311-320.	2.1	16
40	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. Haematologica, 2020, 105, e307-e309.	1.7	3
41	Apixaban Anti-Xa Level Monitoring in Treatment of Provoked Acute Upper Extremity Deep Vein Thrombosis for Patient on Dialysis: A Case Report. Blood, 2020, 136, 14-14.	0.6	0
42	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 2141-2151.	1.9	41
43	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thrombosis Research, 2019, 182, 12-19.	0.8	10
44	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thrombosis and Haemostasis, 2019, 119, 1886-1887.	1.8	9
45	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	1.7	1
46	Inferior Vena Cava Filters in the Management of Venous Thromboembolismâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1007.	3.8	0
47	The value of sPESI for risk stratification in patients with pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 149-157.	1.0	15
48	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. Thrombosis Research, 2019, 176, 8-10.	0.8	2
49	Extended therapy for unprovoked venous thromboembolism: when is it indicated?. Blood Advances, 2019, 3, 499-499.	2.5	2
50	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380, 711-719.	13.9	614
51	Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research, 2019, 6, 84-94.	0.6	4
52	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. Blood, 2019, 134, 329-329.	0.6	0
53	Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research, 2019, 6, 160-173.	0.6	1
54	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. New England Journal of Medicine, 2018, 378, 699-707.	13.9	294

#	Article	IF	Citations
55	Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results. Journal of Medical Economics, 2018, 21, 587-594.	1.0	2
56	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thrombosis Research, 2018, 164, S124-S129.	0.8	28
57	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thrombosis Research, 2018, 163, 19-21.	0.8	6
58	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thrombosis Research, 2018, 163, 41-46.	0.8	36
59	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research, 2018, 162, 7-14.	0.8	20
60	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	0.7	5
61	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	0.7	6
62	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thrombosis Research, 2018, 162, 104-109.	0.8	27
63	Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2018, 320, 1583.	3.8	224
64	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vsÂAspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. Chest, 2018, 154, 1371-1378.	0.4	4
65	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	2.5	71
66	Diagnosis of Venous Thromboembolism: 20 Years of Progress. Annals of Internal Medicine, 2018, 168, 131.	2.0	43
67	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood, 2018, 132, 1842-1850.	0.6	16
68	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	0.8	11
69	Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). Blood, 2018, 132, 424-424.	0.6	7
70	Evaluation of Definitions for Oral Anticoagulantâ€“Associated Major Bleeding: A Population-Based Cohort Study. Blood, 2018, 132, 426-426.	0.6	3
71	Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts. Clinical Neurology and Neurosurgery, 2017, 154, 23-27.	0.6	8
72	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. International Journal of Clinical Practice, 2017, 71, e12915.	0.8	2

#	Article	IF	Citations
73	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. Chest, 2017, 152, 81-91.	0.4	68
74	External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. Internal and Emergency Medicine, 2017, 12, 613-619.	1.0	3
75	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. Thrombosis Research, 2017, 152, 52-60.	0.8	25
76	Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thrombosis Research, 2017, 152, 4-6.	0.8	12
77	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. Genetic Epidemiology, 2017, 41, 455-466.	0.6	1
78	Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. American Journal of Medicine, 2017, 130, 990.e9-990.e21.	0.6	107
79	N-terminal of prohormone brain natriuretic peptide predicts functional limitation one year following pulmonary embolism: Results from the ELOPE study. Thrombosis Research, 2017, 153, 47-49.	0.8	4
80	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	13.9	577
81	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	0.6	45
82	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism. Chest, 2017, 151, 1058-1068.	0.4	192
83	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. Epigenomics, 2017, 9, 1403-1422.	1.0	6
84	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. Scientific Reports, 2017, 7, 11207.	1.6	32
85	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. Clinical Therapeutics, 2017, 39, 1396-1408.	1.1	6
86	Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clinical Therapeutics, 2017, 39, 1426-1436.e2.	1.1	2
87	Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis. BMC Pulmonary Medicine, 2017, 17, 37.	0.8	2
88	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Internal and Emergency Medicine, 2017, 12, 311-318.	1.0	14
89	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	0.8	14
90	Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 830-837.	0.7	13

#	Article	IF	Citations
91	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. PLoS ONE, 2017, 12, e0182472.	1.1	10
92	Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS ONE, 2017, 12, e0185022.	1.1	16
93	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. Thrombosis Research, 2016, 143, 152-158.	0.8	35
94	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood, 2016, 127, 1417-1425.	0.6	156
95	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e437-e445.	2.2	29
96	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. International Journal of Cardiology, 2016, 222, 846-849.	0.8	1
97	Comparison of Four Bleeding Risk Scores to Identify Rivaroxabanâ€treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Academic Emergency Medicine, 2016, 23, 144-150.	0.8	25
98	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 42, 513-519.	1.0	6
99	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.4	24
100	Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. Thrombosis Research, 2016, 144, 152-157.	0.8	19
101	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e228-e236.	2.2	55
102	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.4	4,060
103	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood, 2016, 128, 139-139.	0.6	3
104	Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study. Blood, 2016, 128, 417-417.	0.6	2
105	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	0.6	0
106	External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans. Blood, 2016, 128, 533-533.	0.6	0
107	Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status. Blood, 2016, 128, 2337-2337.	0.6	0
108	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. Blood, 2016, 128, 144-144.	0.6	2

#	Article	IF	Citations
109	Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thrombosis Research, 2015, 136, 1099-1102.	0.8	41
110	Computed Tomographic Pulmonary Angiography for Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 314, 74.	3.8	7
111	D-Dimer for Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2015, 313, 1668.	3.8	21
112	Dalteparin for pregnant women with thrombophilia â€“ Authors' reply. Lancet, The, 2015, 385, 690.	6.3	1
113	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. Nature Communications, 2015, 6, 6326.	5.8	115
114	Nonleg Venous Thrombosis in Critically Ill Adults. JAMA - Journal of the American Medical Association, 2015, 313, 411.	3.8	7
115	Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the <scp>EINSTEIN PE</scp> Study. Academic Emergency Medicine, 2015, 22, 299-307.	0.8	31
116	Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. Blood, 2015, 126, 3468-3468.	0.6	4
117	"Post-Pulmonary Embolism Syndrome" after a First Episode of PE: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 650-650.	0.6	7
118	Dyspnea, Quality of Life and Walking Capacity during 1 Year Follow-up after a First Episode of Pulmonary Embolism: Results of the E.L.O.P.E. Study. Blood, 2015, 126, 750-750.	0.6	1
119	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. Blood, 2015, 126, 893-893.	0.6	4
120	Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study. Blood, 2015, 126, 649-649.	0.6	0
121	Therapies for Venous Thromboembolismâ€"Reply. JAMA - Journal of the American Medical Association, 2014, 311, 2543.	3.8	0
122	Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thrombosis Journal, 2014, 12, 26.	0.9	14
123	Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 312, 1122.	3.8	126
124	Treatment of Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2014, 311, 717.	3.8	176
125	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet, The, 2014, 383, 880-888.	6.3	425
126	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology,the, 2014, 1, e37-e46.	2.2	244

#	Article	IF	Citations
127	Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. Resuscitation, 2014, 85, 1354-1358.	1.3	38
128	Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet, The, 2014, 384, 1673-1683.	6.3	210
129	Clinical Decision Rules and D-dimer in Venous Thromboembolism: Current controversies and future research priorities. Thrombosis Research, 2014, 134, 763-768.	0.8	25
130	Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood, 2014, 124, 2124-2130.	0.6	59
131	Outpatient treatment of symptomatic pulmonary embolism: A systematic review and meta-analysis. Thrombosis Research, 2013, 132, 515-519.	0.8	131
132	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	0.9	60
133	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. Blood, 2013, 122, 36-36.	0.6	3
134	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. Blood, 2013, 122, 460-460.	0.6	2
135	Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy. Blood, 2013, 122, 1139-1139.	0.6	0
136	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	0.6	0
137	Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. Circulation, 2012, 126, 448-454.	1.6	179
138	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	13.9	2,080
139	The Diagnosis of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 691-701.	1.5	18
140	Diagnosis of DVT. Chest, 2012, 141, e351S-e418S.	0.4	570
141	Antithrombotic Therapy for VTE Disease. Chest, 2012, 141, e419S-e496S.	0.4	3,745
142	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. Journal of Medical Economics, 2011, 14, 238-244.	1.0	11
143	Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study. Blood, 2011, 118, 1236-1236.	0.6	0
144	Frequency and Predictors of Post-Thrombotic Syndrome in Patients with a First, Unprovoked Deep Vein Thrombosis and No Prior Primary Venous Insufficiency: Results From the REVERSE Cohort Study,. Blood, 2011, 118, 3332-3332.	0.6	0

#	Article	IF	Citations
145	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	13.9	2,807
146	Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. Blood, 2010, 116, 475-475.	0.6	9
147	Outcome of Saddle Pulmonary Embolism: A Nested Case-Control Study.. Blood, 2010, 116, 1102-1102.	0.6	0
148	Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. Blood, 2010, 116, 4209-4209.	0.6	0
149	Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period. Blood, 2010, 116, 4202-4202.	0.6	2
150	Safety of Outpatient Treatment In Acute Pulmonary Embolism.. Blood, 2010, 116, 3796-3796.	0.6	0
151	Outcomes of Pulmonary Embolism In Surgical Patients: A Retrospective Cohort Study. Blood, 2010, 116, 3180-3180.	0.6	7
152	Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. American Journal of Managed Care, 2010, 16, 857-63.	0.8	14
153	Practical application of the 10-mg warfarin initiation nomogram. Blood Coagulation and Fibrinolysis, 2009, 20, 403-408.	0.5	11
154	A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update.. Blood, 2009, 114, 3125-3125.	0.6	2
155	A Randomized, Controlled Two-Center Pilot Trial of a 6-Month Exercise Training Program to Treat the Post-Thrombotic Syndrome: The EXPO Pilot Trial.. Blood, 2009, 114, 3984-3984.	0.6	1
156	Pulmonary Embolism: A Clinician's Perspective. Seminars in Nuclear Medicine, 2008, 38, 404-411.	2.5	15
157	Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.. Blood, 2008, 112, 1292-1292.	0.6	2
158	Alignment to ACCP Prophylaxis Guidelines and VTE Outcomes in THR and TKR Patients. Blood, 2008, 112, 170-170.	0.6	15
159	Trousseauâ€™s Syndrome Revisited: Should We Screen Extensively for Malignancy in Patients with Venous Thromboembolism? a Systematic Review and Meta-Analysis. Blood, 2008, 112, 403-403.	0.6	1
160	Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.. Blood, 2008, 112, 1291-1291.	0.6	0
161	Practical Application of the 10 Mg Warfarin Initiation Nomogram. Blood, 2008, 112, 4054-4054.	0.6	0
162	VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies.. Blood, 2008, 112, 1811-1811.	0.6	0

#	Article	IF	Citations
163	Dose Escalation of Low Molecular Weight Heparin to Manage VTE Treatment Failure in Cancer Patients. Blood, 2008, 112, 4050-4050.	0.6	0
164	The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. Blood Coagulation and Fibrinolysis, 2006, 17, 533-538.	0.5	8
165	Advances in the Diagnosis of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2006, 21, 31-40.	1.0	40
166	Does This Patient Have Deep Vein Thrombosis?. JAMA - Journal of the American Medical Association, 2006, 295, 199.	3.8	403
167	Factor XIII Val34Leu Variant Is Protective against Venous Thromboembolism: A HuGE Review and Meta-Analysis. American Journal of Epidemiology, 2006, 164, 101-109.	1.6	84
168	A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombois of the Upper Extremity (UEDVT).. Blood, 2006, 108, 878-878.	0.6	4
169	The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.. Blood, 2006, 108, 874-874.	0.6	0
170	A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Archives of Internal Medicine, 2005, 165, 733.	4.3	156
171	The Role of Qualitative D-Dimer Assays, Clinical Probability, and Noninvasive Imaging Tests for the Diagnosis of Deep Vein Thrombosis and Pulmonary Embolism. Seminars in Vascular Medicine, 2005, 05, 340-350.	2.1	12
172	Computerized Tomographic Pulmonary Angiography Compared with Ventilation-Perfusion Lung Scanning as Inital Diagnostic Modality for Patients with Suspected Pulmonary Embolism: A Randomized Controlled Trial.. Blood, 2005, 106, 1619-1619.	0.6	3
173	Factor XIII Val34Leu Polymorphism and the Risk of Myocardial Infarction: A Meta-Analysis.. Blood, 2005, 106, 1637-1637.	0.6	0
174	Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.. Blood, 2005, 106, 913-913.	0.6	5
175	A Meta-Analysis to Determine the Risk of Heparin Induced Thrombocytopenia (HIT) and Isolated Thrombocytopenia in Prophylaxis Studies Comparing Unfractioneted Heparin (UFH) and Low Molecular Weight Heparin (LMWH).. Blood, 2004, 104, 2587-2587.	0.6	5
176	Randomized Trial of Warfarin Nomograms. Annals of Internal Medicine, 2004, 140, 491.	2.0	0
177	Factor XIII Val34Leu Polymorphism Is Protective Against Venous Thromboembolism; a Meta-Analysis.. Blood, 2004, 104, 3512-3512.	0.6	0
178	Overview and comparison of D-dimer assay kits for DVT and PE. Clinical Advances in Hematology and Oncology, 2004, 2, 160, 178.	0.3	4
179	Diagnosis of pulmonary embolism: when is imaging needed?. Clinics in Chest Medicine, 2003, 24, 13-28.	0.8	26
180	Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. New England Journal of Medicine, 2003, 349, 1227-1235.	13.9	1,329

#	Article	IF	Citations
181	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	13.9	728
182	The Outpatient Bleeding Risk Index. Archives of Internal Medicine, 2003, 163, 917.	4.3	114
183	Safety and Efficacy of Methods for Reducing Perioperative Allogeneic Transfusion: A Critical Review of the Literature. American Journal of Therapeutics, 2002, 9, 377-388.	0.5	42
184	Feasibility of blinding in a randomized controlled trial comparing preoperative autologous blood donation and acute normovolemic hemodilution in adult cardiac surgery. Transfusion, 2000, 40, 1058-1062.	0.8	6
185	Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension. Canadian Respiratory Journal, 2000, 7, 49-57.	0.8	28
186	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	13.9	1,052
187	Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism. Thrombosis and Haemostasis, 1995, 73, 035-038.	1.8	94
188	A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. Circulation, 1995, 91, 2184-2187.	1.6	203
189	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. Thrombosis and Haemostasis, 1994, 71, 300-304.	1.8	150
190	Diagnostic Management Strategies in Patients with Suspected Deep Vein Thrombosis. , 0, , 315-327.		0